@drsophiemerrick.bsky.social
📤 32
📥 24
📝 4
reposted by
MRC Clinical Trials Unit at UCL
9 days ago
Dr Sophie Merrick (
@drsophiemerrick.bsky.social
) presented at
#ESMO25
results from her qualitative study within the RAMPART
#ClinicalTrial
. Her research highlights how immunotherapy impacts the lives of kidney cancer patients, an essential view in cancer care. 🔗 View the poster:
buff.ly/fPtvyZ2
0
5
1
reposted by
MRC Clinical Trials Unit at UCL
22 days ago
📈 Exciting news from
#ESMO25
! First results from the RAMPART trial show that a combination of 2 immunotherapy drugs (durvalumab and tremelimumab) helps prevent kidney cancer from coming back after surgery. 🔗 Read the full story:
www.mrcctu.ucl.ac.uk/news/news-st...
loading . . .
A combination of two immunotherapy drugs benefits people with kidney cancer | MRC Clinical Trials Unit at UCL
https://www.mrcctu.ucl.ac.uk/news/news-stories/2025/october/a-combination-of-two-immunotherapy-drugs-benefits-people-with-kidney-cancer/
0
1
1
reposted by
MRC Clinical Trials Unit at UCL
3 months ago
Another Wednesday, another chance to share what makes us proud! 😊 This week, we’re spotlighting Sophie Merrick
drsophiemerrick.bsky.social
, one of our Senior Clinical Research Fellows at the Unit. Here’s what Sophie is
#ProudestOf
from the Unit’s work 👇
1
4
1
reposted by
MRC Clinical Trials Unit at UCL
6 months ago
💻 Come along to our next Capacity Strengthening Hub webinar with
@tghn-news.bsky.social
to hear about experts' experience, general principles and a practical framework for communicating
#ClinicalTrials
results with participants. 🗓️ 2 June 🕙 10:00-11:30 BST 📍 Online Register now:
bit.ly/4k28ALd
0
2
3
Join us for our next @NIHRresearch Learning Lecture 'Making Clinical Trials More Inclusive' with @kamleshkhunti ⏰ 11th June 1-2pm 🖥️ Online 💷 Free Sign up 👇
sites.google.com/nihr.ac.uk/a...
loading . . .
Associate Principal Investigator Scheme - Schedule
Next lecture
https://sites.google.com/nihr.ac.uk/associatepischeme/events/research-learning-lectures/schedule
6 months ago
0
0
0
'The words "tolerable" or "tolerability" should not be used unless quality of life data are reported'
#QoLConf25
6 months ago
0
1
0
Pleased to share our most recent paper on 'Determining the optimal use of approved drugs in oncology' which is now published in Lancet Oncology. Check it out h👇
add a skeleton here at some point
6 months ago
0
0
0
Join us next week for our free
@nihr.bsky.social
webinar 'Clinical trials aimed at optimising approved drugs' ⏰ Thursday 20.2.25 1-2pm 💷 Free 👇 Sign up here
@mrcctu.bsky.social
sites.google.com/nihr.ac.uk/a...
loading . . .
Associate Principal Investigator Scheme - Schedule
Next lecture
https://sites.google.com/nihr.ac.uk/associatepischeme/events/research-learning-lectures/schedule
9 months ago
0
3
1
reposted by
Annabelle South
9 months ago
Are you a member of a Research Ethics Committee in the UK? If so, we'd love to speak to you about your views of personalised trials in mental health. Please do consider signing up.
#ResearchEthics
#MentalHealth
add a skeleton here at some point
0
1
2
reposted by
Sarah Danson
9 months ago
This is brilliant news for the post NCRI oncology world
add a skeleton here at some point
0
6
2
reposted by
MRC Clinical Trials Unit at UCL
10 months ago
Fraudulent participation is when study participants purposely give false responses. This can be common in qualitative studies using online recruitment & monetary incentives. The P-FROST recommendations provide advice on this emerging phenomenon.👇https://buff.ly/4j2qYnl
@drsophiemerrick.bsky.social
loading . . .
Fraudulent Participation in Online Qualitative Studies: Practical Recommendations on an Emerging Phenomenon
This paper offers a critical reflection thereon by three separate qualitative research groups that experienced fraudulent participation in collaboration with a patient representative, a bioethicist, a legal expert, a journal deputy editor, and a chief executive of a national charity.
https://buff.ly/4j2qYnl
0
1
1
reposted by
Annabelle South
10 months ago
Late-phase clinical trials have the potential to improve health, but there are often delays in these results influencing clinical practice. We developed a knowledge transfer and exchange strategy to help reduce these delays and maximise impact
link.springer.com/article/10.1...
loading . . .
Developing a knowledge transfer and exchange strategy for a clinical trials unit - Trials
Need for a strategic approach to knowledge transfer and exchange Late-phase clinical trials and systematic reviews find results that have the potential to improve health outcomes for people. However, ...
https://link.springer.com/article/10.1186/s13063-024-08681-x
0
4
2
you reached the end!!
feeds!
log in
